Barclays raised PT $IMGN $20 was$9/Overweight MIRASOL data4 Elahere in ovarian cancer was well received@ #ASCO23 /KOLs commentary suggests the drug is likely*practice changing; KOLs see strong oppy4 Elahere to move in2 earlier lines of Tx /have no concerns about ocular toxicity.